<?xml version='1.0' encoding='utf-8'?>
<document id="23681961"><sentence text="CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy." /><sentence text="Studies with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) monoinfection and HIV coinfection were highlighted at the 2013 Conference on Retroviruses and Opportunistic Infections (CROI)" /><sentence text=" In HCV monoinfected patients, several interferon alfa-sparing, all-oral regimens demonstrated cure rates of greater than 90% with 12 weeks of treatment, including for hard-to-treat patients" /><sentence text=" Cure rates of 75% were attained in HIV/HCV coinfected patients with the addition of the investigational HCV protease inhibitor (PI) simeprevir to peginterferon alfa and ribavirin"><entity charOffset="170-179" id="DDI-PubMed.23681961.s4.e0" text="ribavirin" /></sentence><sentence text=" Drug-drug interaction data to inform safe coadminstration of antiretroviral therapy with DAA-based HCV treatment were presented" /><sentence text=" There was continued emphasis on pathogenesis, management, and prevention of the long-term complications of HIV disease and its therapies, including cardiovascular disease, renal disease, alterations in bone metabolism, and vitamin D deficiency, along with a growing focus on biomarkers to predict development of end-organ disease"><entity charOffset="224-233" id="DDI-PubMed.23681961.s6.e0" text="vitamin D" /></sentence><sentence text=" Understanding the elevated risk for non-AIDS-defining malignancies in the HIV-infected population and optimal management was a focal point of this year's data" /><sentence text=" Finally, the conference provided important information on tuberculosis coinfection and cryptococcal meningitis" /><sentence text="" /></document>